Safety of Semaglutide.
Smits MM, Van Raalte DH.
Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021.
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM.
J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23.
Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.
Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M.
Minerva Endocrinol (Torino). 2023 Jun;48(2):206-213. doi: 10.23736/S2724-6507.20.03219-8. Epub 2020 Jul 23.
Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study.
Nassar M, Nassar O, Abosheaishaa H, Misra A.
Diabetes Metab Syndr. 2024 Sep;18(9):103116. doi: 10.1016/j.dsx.2024.103116. Epub 2024 Sep 19.
Adverse Effects of GLP-1 Receptor Agonists.
Filippatos TD, Panagiotopoulou TV, Elisaf MS.
Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.
N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.
Type 3c: Understanding pancreatogenic diabetes.
Vonderau JS, Desai CS.
JAAPA. 2022 Nov 1;35(11):20-24. doi: 10.1097/01.JAA.0000885140.47709.6f.
Gastrointestinal Consequences of Type 2 Diabetes Mellitus and Impaired Glycemic Homeostasis: A Mendelian Randomization Study.
Chen J, Yuan S, Fu T, Ruan X, Qiao J, Wang X, Li X, Gill D, Burgess S, Giovannucci EL, Larsson SC.
Diabetes Care. 2023 Apr 1;46(4):828-835. doi: 10.2337/dc22-1385.
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Deacon CF.
Nat Rev Endocrinol. 2020 Nov;16(11):642-653. doi: 10.1038/s41574-020-0399-8. Epub 2020 Sep 14.
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S.
Front Endocrinol (Lausanne). 2023 Oct 16;14:1214334. doi: 10.3389/fendo.2023.1214334. eCollection 2023.
